Answers are grounded in this paper and cite their sources.
The LimFlow pDVA System was utilized in treating patients with no-option CLTI. A high technical success rate was observed, with a significant percentage of patients surviving free of major amputation at 12 months. These results suggest early safety and provide an initial assessment of the efficacy of the LimFlow pDVA System that supports the expansion of carefully executed studies to determine whether this is a viable option that can be used in this critically disadvantaged and growing patient population.
No takes yet. Share an insight, caveat, or question.
Clair et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: